First clinical trials of brain cancer immune therapy succeed and account for individual genetic features
Main challenges in treating brain cancer patients are high risk of disease recurrence and death within 1-1.5 years after the tumor onset. Existing therapeutic technologies are based on stimulating the patient's immune system to fight malignant tumors, which is rarely effective enough and causes side effects.